Status:
UNKNOWN
Evaluation of Therapeutic Effects of Melatonin by Inhibition of NLRP3 Inflammasome in COVID19 Patients
Lead Sponsor:
Mohammad Sadegh Bagheri Baghdasht
Conditions:
COVID-19
Eligibility:
All Genders
16-100 years
Phase:
NA
Brief Summary
The leading cause of death in patients with COVID19 is a severe inflammatory response caused by a cytokine storm that results in acute respiratory distress syndrome and acute pulmonary insufficiency, ...
Eligibility Criteria
Inclusion
- Diagnosis of COVID-19 based on either ground glass appearance in chest CT scan or positive RT-PCR test for COVID-19
- Oxygen saturation drop below 93%
- Systolic blood pressure drop below 100 or blood pressure drop of 30 mm Hg from the patient's previous normal systolic blood pressure
- Fever
- Dry cough
- Positive PCR for COVID-19
- Laboratory indices include CRP and ESR indicating COVID-19
Exclusion
- Patient dissatisfaction
- Existence of drug interactions
- Lack of proper conditions for receiving medication
Key Trial Info
Start Date :
May 12 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 25 2020
Estimated Enrollment :
55 Patients enrolled
Trial Details
Trial ID
NCT04409522
Start Date
May 12 2020
End Date
September 25 2020
Last Update
June 1 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mohammad Sadegh Bagheri Baghdasht
Tehran, Iran, 0